Department of Child and Adolescent Medicine, Section of Pediatric Cardiology, University Hospital Jena, Am Klinikum, Jena, Germany
Search for other papers by Alexandra Kiess in
Google Scholar
PubMed
Search for other papers by Jessica Green in
Google Scholar
PubMed
Search for other papers by Anja Willenberg in
Google Scholar
PubMed
Search for other papers by Uta Ceglarek in
Google Scholar
PubMed
Search for other papers by Ingo Dähnert in
Google Scholar
PubMed
Department of Women and Child Health, Hospital for Children and Adolescents and Center for Pediatric Research (CPL), University of Leipzig, Liebigstrasse, Leipzig, Germany
Search for other papers by Wieland Kiess in
Google Scholar
PubMed
Department of Women and Child Health, Hospital for Children and Adolescents and Center for Pediatric Research (CPL), University of Leipzig, Liebigstrasse, Leipzig, Germany
Search for other papers by Mandy Vogel in
Google Scholar
PubMed
acromegaly have reported associations between growth hormone markers and cardiac markers together with cardiovascular morbidity and mortality rates. Andreassen et al. found concordant results to ours with IGF-1 levels that were inversely associated with NT
Search for other papers by Shota Dzemaili in
Google Scholar
PubMed
Search for other papers by Jitske Tiemensma in
Google Scholar
PubMed
Search for other papers by Richard Quinton in
Google Scholar
PubMed
Search for other papers by Nelly Pitteloud in
Google Scholar
PubMed
Faculty of Nursing Science, Laval University, Québec City, Canada
Search for other papers by Diane Morin in
Google Scholar
PubMed
Endocrinology, Diabetes & Metabolism Service of the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Search for other papers by Andrew A Dwyer in
Google Scholar
PubMed
normative scores for the IPQ-R for the general population (i.e. healthy adults), comparisons were made to patients with acute or chronic pain ( 24 ), men with CHH ( 22 ) and patients with acromegaly ( 24 ) to provide a clinical context for these data. Age at
Search for other papers by L M Mongioì in
Google Scholar
PubMed
Search for other papers by R A Condorelli in
Google Scholar
PubMed
Search for other papers by S La Vignera in
Google Scholar
PubMed
Search for other papers by A E Calogero in
Google Scholar
PubMed
life, HRQoL): GH deficiency (Assessment of Growth Hormone Deficiency in Adults, AGHDA) ( 18 ), acromegaly (Acromegaly Quality of Life questionnaire, AcroQoL) and Cushing’s syndrome (Cushing Quality of Life questionnaire, CushingQoL) ( 19 ). Along the
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Niels Jørgensen in
Google Scholar
PubMed
Patients characteristics. Numbers Primary diagnosis Acromegaly 8 Prolactinoma 3 Mixed GH and prolactin secreting adenoma 2 Empty sella 2 Non-secreting adenoma 2
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Yvonne Winhofer in
Google Scholar
PubMed
High Field MR Centre, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
Search for other papers by Martin Krššák in
Google Scholar
PubMed
Search for other papers by Michael Krebs in
Google Scholar
PubMed
Metabolic disturbances in patients suffering from excessive production of growth hormone (GH), termed acromegaly, seem to be similar to those in the insulin resistant state, i.e. hyperglycemia, hyperinsulinemia and hypertriglyceridemia ( 63 ). Conversely
PhD School of Clinical and Experimental Biomedical Sciences, University of Messina, Messina, Sicily, Italy
Search for other papers by G Giuffrida in
Google Scholar
PubMed
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy
Search for other papers by F Ferraù in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by R Laudicella in
Google Scholar
PubMed
Search for other papers by O R Cotta in
Google Scholar
PubMed
Search for other papers by E Messina in
Google Scholar
PubMed
Neuroradiology Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Search for other papers by F Granata in
Google Scholar
PubMed
Neurosurgery Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Search for other papers by F F Angileri in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by A Vento in
Google Scholar
PubMed
Search for other papers by A Alibrandi in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by S Baldari in
Google Scholar
PubMed
PhD School of Clinical and Experimental Biomedical Sciences, University of Messina, Messina, Sicily, Italy
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy
Search for other papers by S Cannavò in
Google Scholar
PubMed
, 17 ). Three patients affected by pituitary carcinoma were treated with 90 Y-DOTATOC (2 cycles), 90 Y-DOTATATE or 177 Lu-DOTATATE (four cycles), respectively ( 13 , 14 , 16 ). The first one was affected by Nelson syndrome, the second by acromegaly
Search for other papers by Debra M Gordon in
Google Scholar
PubMed
Search for other papers by Pablo Beckers in
Google Scholar
PubMed
Search for other papers by Emilie Castermans in
Google Scholar
PubMed
Search for other papers by Sebastian J C M M Neggers in
Google Scholar
PubMed
Search for other papers by Liliya Rostomyan in
Google Scholar
PubMed
Search for other papers by Vincent Bours in
Google Scholar
PubMed
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Vinciane Dideberg in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
. SDHB c.287G>A p.Gly96Asp Pituitary P04 F 28 Pituitary macroadenoma (prolactinoma), resistant to dopamine agonists; neurosurgery (×2) None MEN1 c.1618C>T p.Pro540Ser P21 M 25 Acromegaly (macroadenoma
Search for other papers by Karim Gariani in
Google Scholar
PubMed
Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Search for other papers by François R Jornayvaz in
Google Scholar
PubMed
) - Pituitary gland (TSH) - Thyroid gland (free T4) - Primary hypothyroidism (thyroid disease) - Secondary hypothyroidism (pituitary (TSH) or hypothalamic disease (TRH)) Growth hormone (GH) - Pituitary gland (GH) - Ectopic secretion - Acromegaly
Search for other papers by Anastasia P Athanasoulia-Kaspar in
Google Scholar
PubMed
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany
Search for other papers by Matthias K Auer in
Google Scholar
PubMed
Search for other papers by Günter K Stalla in
Google Scholar
PubMed
Search for other papers by Mira Jakovcevski in
Google Scholar
PubMed
, pituitary tumors such as somatotropic and corticotropic adenomas resulting in hormone excess conditions such as acromegaly ( 12 , 13 ) and Cushing’s syndrome ( 13 ) have been associated with accelerated telomere shortening ( 14 , 15 ), suggesting that TL
Search for other papers by Veronica Kieffer in
Google Scholar
PubMed
Search for other papers by Kate Davies in
Google Scholar
PubMed
Search for other papers by Christine Gibson in
Google Scholar
PubMed
Search for other papers by Morag Middleton in
Google Scholar
PubMed
Search for other papers by Jean Munday in
Google Scholar
PubMed
Search for other papers by Shashana Shalet in
Google Scholar
PubMed
Search for other papers by Lisa Shepherd in
Google Scholar
PubMed
Search for other papers by Phillip Yeoh in
Google Scholar
PubMed
objectives. Performance appraisal. Specialist competencies The adult endocrine nurse specialist competency framework is presented in the following tables: Competency 1 : Acromegaly. Competency 2 : Benign adrenal tumours. Competency 3 : Cushing's syndrome